Cardiovascular risk factors in chronic kidney disease: Does phosphate qualify

Kidney International

Volumn 79, Issue SUPPL. 121, 2011, Pages S9-

  Hruska, Keith ^a   Mathew, Suresh ^a   Lund, Richard ^b   Fang, Yifu ^a   Sugatani, Toshifumi ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

arterial calcification; cardiovascular disease; mortality; phosphate

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; PHOSPHATE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; HUMAN; MORTALITY; NEOINTIMA; NONHUMAN; OBSERVATIONAL STUDY; OSTEOBLAST; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; REVIEW; ANGINA PECTORIS; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR MORTALITY; CLINICAL RESEARCH; HEART FAILURE; HEART INFARCTION; HYPERPHOSPHATEMIA; KIDNEY TUBULE ABSORPTION; PERIPHERAL VASCULAR DISEASE; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STROKE; TRANSLATIONAL RESEARCH;

EID: 79953281956     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.24     Document Type: Review

References (25)

1. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000; 35: S117-S131. (Pubitemid 30183825)
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119. (Pubitemid 28527268)
3. Berl T. American Society of Nephrology Presidential Address 2005. J Am Soc Nephrol 2006; 17: 926-931.
4. London GM, Marchais SJ, Guerin AP, Metivier F, Adda H. Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant 2002; 17: 1713-1724. (Pubitemid 35174279)
5. Marchais SJ, Metivier F, Guerin AP et al. Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol Dial Transplant 1999; 14: 2178-2183. (Pubitemid 29403408)
6. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
7. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218. (Pubitemid 39031360)
8. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528. (Pubitemid 41725150)
9. Dhingra R, Sullivan LM, Fox CS et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167: 879-885. (Pubitemid 46762749)
10. Tonelli M, Sacks F, Pfeffer M et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-2633. (Pubitemid 41532599)
11. Tonelli M, Curhan G, Pfeffer M et al. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation 2009; 120: 1784-1792.
12. Ix JH, De Boer IH, Peralta CA et al. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol 2009; 4: 609-615.
13. Foley RN, Collins AJ, Herzog CA et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009; 20: 397-404.
14. Towler DA, Bidder M, Latifi T et al. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem 1998; 273: 30427-30434. (Pubitemid 28545516)
15. Davies MR, Lund RJ, Mathew S et al. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol 2005; 16: 917-928. (Pubitemid 41710302)
16. Mathew S, Lund RJ, Strebeck F et al. Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 2007; 18: 122-130. (Pubitemid 46053427)
17. Hruska KA. Vascular smooth muscle cells in the pathogenesis of vascular calcification. Circ Res 2009; 104: 710-711.
18. Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003; 14: S300-S304. (Pubitemid 37052394)
19. Li X, Yang HY, Giachelli CM. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006; 98: 905-912.
20. Mathew S, Tustison KS, Sugatani T et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol 2008; 19: 1092-1105.
21. Nakashima K, Zhou X, Kunkel G et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002; 108: 17-29. (Pubitemid 34137009)
22. Razzaque MS, Lanske B. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 2007; 194: 1-10. (Pubitemid 47162881)
23. Isakova T, Gutierrez OM, Chang Y et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009; 20: 388-396.
24. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824. (Pubitemid 43169927)
25. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.